Disclosure
WCommentary
AI commentary · Not investment advice
What happened
Hanlim-style disclosure aside, Hwanin Pharm reported preliminary consolidated results for the third quarter of 2026 (July 1 to September 30) in a fair disclosure filed on October 29, 2026. Revenue was KRW 71.6 billion, operating profit was KRW 7.5 billion, and net income was KRW 6.5 billion.
In the company's terms
Against the prior quarter, revenue of KRW 71.4 billion rose 0.2%, while operating profit of KRW 7.9 billion fell 4.6% and net income of KRW 7.7 billion fell 15.7%. Against the same quarter a year earlier, revenue of KRW 65.7 billion rose 8.9%, operating profit of KRW 3.6 billion rose 111.8%, and net income of KRW 3.3 billion rose 98.1%.
What changes for shareholders
The filing is listed at 4.0% relative to market capitalization. Because these are preliminary figures, the final confirmed results may differ.
Show Korean comments
Comments
No comments yet
Comments from shareholders will appear here.
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist